|
News ReleasesAlzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer's disease and Anavex’s Phase I clinical program as "Trial 2011-01-11 Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly. ANAVEX 2-73 advances Phase I clinical trial for Alzheimer's disease2011-05-26 Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease.... Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease2010-08-10 Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for it... Anavex appoints Dr. Rachelle Doody to Scientific Advisory Board 2011-02-23 Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the comp... Anavex comments on new Alzheimer's disease diagnostic guidelines 2011-05-17 Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and th... Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer's disease2011-01-11 Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, ... Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer's Disease2011-03-21 Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by t... Nurses to Fraser Health: Come clean on drug company ties, funding for flu vaccine study2012-11-30 BC Nurses' Union The study involving Novartis Pharmaceuticals is headed up by Fraser's chief medical health officer, a key figure driving the policy to force healthcare workers to take the flu vaccine or wear a mask Sources Select ResourcesBad Pharma, Bad Journalism Cromwell, David Article 2012 Media Lens ‘The drugs don't work: a modern medical scandal’, from Ben Goldacre's new book, Bad Pharma presents a disturbing picture emerges of corporate drug abuse. Sources HotLink - June 30, 2016Serial Publication (Periodical) 2016 Sources Articles about the FBI and the information it gathers, Donald Trump and the media, and the role of pharmaceutical companies in suppressing information. Sources BookshelfPrivate Profits vs Public PolicyThe Pharmaceutical Industry and the Canadian State Lexchin, Joel Book 2016 According to Joel Lexchin, "Given the central role that medicines play in keeping us healthy, it is essential that we understand the policy environment that governs drug development, from the initial ... Government Ministries & AgenciesCanadian Institutes of Health Research"To excel...in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system."
|
|
Sources is an online portal and directory for journalists, writers, news editors, researchers. Use Sources to find experts, media contacts, spokespersons, scientists, lobbyists, officials, speakers, university professors, researchers, newsmakers, CEOs, executive directors, media relations contacts, spokespeople, talk show guests, PR representatives, Canadian sources, story ideas, research studies, databases, universities, colleges, associations, businesses, government, research institutions, lobby groups, non-government organizations (NGOs), in Canada and internationally.
© Sources 1977-2021. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.
|